Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Relinde I. Y. Lieverse; Evert J. Van Limbergen; Cary J. G. Oberije; Esther G. C. Troost; Sine R. Hadrup; Anne-Marie C. Dingemans; Lizza E. L. Hendriks; Franziska Eckert; Crispin Hiley; Christophe Dooms; Yolande Lievens; Monique C. de Jong; Johan Bussink; Xavier Geets; Vincenzo Valentini; Giuliano Elia; Dario Neri; Charlotte Billiet; Amir Abdollahi; David Pasquier; Pierre Boisselier; Ala Yaromina; Dirk De Ruysscher; Ludwig J. Dubois; Philippe Lambin

doi:10.1186/s12885-020-07055-1

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Relinde I. Y. Lieverse^*, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David PasquierPierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois, Philippe Lambin

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BackgroundAbout 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR).MethodsThis investigator-initiated, multicentric, randomised controlled open-label phase II clinical trial will test the hypothesis that the combination of SABR and L19-IL2 increases progression free survival (PFS) in patients with limited metastatic NSCLC. One hundred twenty-six patients will be stratified according to their metastatic load (oligo-metastatic:

Original language	English
Article number	557
Number of pages	10
Journal	BMC Cancer
Volume	20
Issue number	1
DOIs	https://doi.org/10.1186/s12885-020-07055-1
Publication status	Published - 15 Jun 2020

Keywords

Immunotherapy
L19-IL2
Anti-PD-L1
Anti-PD-1
Radiotherapy
SABR
Phase 2
NSCLC
Stage IV
Multicentre
CELL LUNG-CANCER
LOCAL CONSOLIDATIVE THERAPY
ED-B FIBRONECTIN
EXTRA-DOMAIN-B
IMMUNOCYTOKINE L19-IL2
MAINTENANCE THERAPY
RADIATION-THERAPY
DOSE-ESCALATION
SOLID TUMORS
MARKER

Access to Document

10.1186/s12885-020-07055-1Licence: CC BY

Fingerprint

Dive into the research topics of 'Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial'. Together they form a unique fingerprint.

Cite this

Lieverse, R. I. Y., Van Limbergen, E. J., Oberije, C. J. G., Troost, E. G. C., Hadrup, S. R., Dingemans, A.-M. C., Hendriks, L. E. L., Eckert, F., Hiley, C., Dooms, C., Lievens, Y., de Jong, M. C., Bussink, J., Geets, X., Valentini, V., Elia, G., Neri, D., Billiet, C., Abdollahi, A., ... Lambin, P. (2020). Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer, 20(1), Article 557. https://doi.org/10.1186/s12885-020-07055-1

@article{237718b4d95c4812a152c984ebce787d,

title = "Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial",

abstract = "BackgroundAbout 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR).MethodsThis investigator-initiated, multicentric, randomised controlled open-label phase II clinical trial will test the hypothesis that the combination of SABR and L19-IL2 increases progression free survival (PFS) in patients with limited metastatic NSCLC. One hundred twenty-six patients will be stratified according to their metastatic load (oligo-metastatic:",

keywords = "Immunotherapy, L19-IL2, Anti-PD-L1, Anti-PD-1, Radiotherapy, SABR, Phase 2, NSCLC, Stage IV, Multicentre, CELL LUNG-CANCER, LOCAL CONSOLIDATIVE THERAPY, ED-B FIBRONECTIN, EXTRA-DOMAIN-B, IMMUNOCYTOKINE L19-IL2, MAINTENANCE THERAPY, RADIATION-THERAPY, DOSE-ESCALATION, SOLID TUMORS, MARKER",

author = "Lieverse, {Relinde I. Y.} and {Van Limbergen}, {Evert J.} and Oberije, {Cary J. G.} and Troost, {Esther G. C.} and Hadrup, {Sine R.} and Dingemans, {Anne-Marie C.} and Hendriks, {Lizza E. L.} and Franziska Eckert and Crispin Hiley and Christophe Dooms and Yolande Lievens and {de Jong}, {Monique C.} and Johan Bussink and Xavier Geets and Vincenzo Valentini and Giuliano Elia and Dario Neri and Charlotte Billiet and Amir Abdollahi and David Pasquier and Pierre Boisselier and Ala Yaromina and {De Ruysscher}, Dirk and Dubois, {Ludwig J.} and Philippe Lambin",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s).",

year = "2020",

month = jun,

day = "15",

doi = "10.1186/s12885-020-07055-1",

language = "English",

volume = "20",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd",

number = "1",

}

Lieverse, RIY , Van Limbergen, EJ, Oberije, CJG, Troost, EGC, Hadrup, SR, Dingemans, A-MC, Hendriks, LEL, Eckert, F, Hiley, C, Dooms, C, Lievens, Y, de Jong, MC, Bussink, J, Geets, X, Valentini, V, Elia, G, Neri, D, Billiet, C, Abdollahi, A, Pasquier, D, Boisselier, P, Yaromina, A , De Ruysscher, D , Dubois, LJ & Lambin, P 2020, 'Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial', BMC Cancer, vol. 20, no. 1, 557. https://doi.org/10.1186/s12885-020-07055-1

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. / Lieverse, Relinde I. Y.; Van Limbergen, Evert J.; Oberije, Cary J. G. et al.
In: BMC Cancer, Vol. 20, No. 1, 557, 15.06.2020.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR

T2 - a multicentre, randomised controlled open-label phase II trial

AU - Lieverse, Relinde I. Y.

AU - Van Limbergen, Evert J.

AU - Oberije, Cary J. G.

AU - Troost, Esther G. C.

AU - Hadrup, Sine R.

AU - Dingemans, Anne-Marie C.

AU - Hendriks, Lizza E. L.

AU - Eckert, Franziska

AU - Hiley, Crispin

AU - Dooms, Christophe

AU - Lievens, Yolande

AU - de Jong, Monique C.

AU - Bussink, Johan

AU - Geets, Xavier

AU - Valentini, Vincenzo

AU - Elia, Giuliano

AU - Neri, Dario

AU - Billiet, Charlotte

AU - Abdollahi, Amir

AU - Pasquier, David

AU - Boisselier, Pierre

AU - Yaromina, Ala

AU - De Ruysscher, Dirk

AU - Dubois, Ludwig J.

AU - Lambin, Philippe

PY - 2020/6/15

Y1 - 2020/6/15

N2 - BackgroundAbout 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR).MethodsThis investigator-initiated, multicentric, randomised controlled open-label phase II clinical trial will test the hypothesis that the combination of SABR and L19-IL2 increases progression free survival (PFS) in patients with limited metastatic NSCLC. One hundred twenty-six patients will be stratified according to their metastatic load (oligo-metastatic:

AB - BackgroundAbout 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR).MethodsThis investigator-initiated, multicentric, randomised controlled open-label phase II clinical trial will test the hypothesis that the combination of SABR and L19-IL2 increases progression free survival (PFS) in patients with limited metastatic NSCLC. One hundred twenty-six patients will be stratified according to their metastatic load (oligo-metastatic:

KW - Immunotherapy

KW - L19-IL2

KW - Anti-PD-L1

KW - Anti-PD-1

KW - Radiotherapy

KW - SABR

KW - Phase 2

KW - NSCLC

KW - Stage IV

KW - Multicentre

KW - CELL LUNG-CANCER

KW - LOCAL CONSOLIDATIVE THERAPY

KW - ED-B FIBRONECTIN

KW - EXTRA-DOMAIN-B

KW - IMMUNOCYTOKINE L19-IL2

KW - MAINTENANCE THERAPY

KW - RADIATION-THERAPY

KW - DOSE-ESCALATION

KW - SOLID TUMORS

KW - MARKER

U2 - 10.1186/s12885-020-07055-1

DO - 10.1186/s12885-020-07055-1

M3 - Article

C2 - 32539805

SN - 1471-2407

VL - 20

JO - BMC Cancer

JF - BMC Cancer

IS - 1

M1 - 557

ER -